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Recombinant tau protein is widely used to study the biochemical, cellular and pathological aspects of
tauopathies, including Alzheimer's disease and frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTPD-17). Pure tau in high yield is a requirement for in vitro evaluation of the protein's
physiological and toxic functions. However, the preparation of recombinant tau is complicated by the
protein's propensity to aggregate and form truncation products, necessitating the use of multiple, time-
consuming puriﬁcation methods. In this study, we investigated parameters that inﬂuence the expression
of wild type and FTPD-17 pathogenic tau, in an attempt to identify ways to maximise expression yield.
Here, we report on the inﬂuence of the choice of host strain, induction temperature, duration of in-
duction, and media supplementation with glucose on tau expression in Escherichia coli. We also describe
a straightforward process to purify the expressed tau proteins using immobilised metal afﬁnity chro-
matography, with favourable yields over previous reports. An advantage of the described method is that
it enables high yield production of functional oligomeric and monomeric tau, both of which can be used
to study the biochemical, physiological and toxic properties of the protein.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tauopathies are a major neurodegenerative health concern
worldwide. These include Alzheimer's disease, frontotemporal
dementia with Parkinsonism linked to chromosome 17 (FTPD-17),
Pick's disease, progressive supranuclear palsy and corticobasal
degeneration [1]. A common feature shared by these diseases is the
abundance of tau-positive neuroﬁbrillary tangles (NFTs) that deﬁne
neuropathology [1,2]. While tau is involved in microtubule (MT)
assembly and stabilisation in physiological conditions, dysfunc-
tional tau has been implicated in tauopathy-associated NFTs
resulting from the accumulation of insoluble toxic aggregates [3].
Recombinant tau closely mimics important properties of the
naturally-occurring human protein. To this end, recombinant tau
has been used extensively to study the molecular, biochemical and
cellular aspects of the protein's functions, including (i) binding toiversity of Warwick, Coventry
arikari).
r Inc. This is an open access articleMTs in physiological and pathological conditions (ii) tau-tau in-
teractions leading to their aggregation into toxic paired helical ﬁl-
aments (PHFs) that are similar to those isolated from the brains of
Alzheimer's disease patients, and (iii) the transcellular spread of
this toxicity in affected organisms [4e10]. The binding of tau to MTs
is disrupted in disease and also by the presence of speciﬁc FTPD-17
mutations some of which can enhance the protein's aggregation
into PHFs [6,9,11,12]. Furthermore, truncated tau constructs such as
the repeat domains are aggregation-prone and demonstrate
enhanced aggregation kinetics compared to the full-length iso-
forms [13,14]. The tau four-repeat domain (K18 construct), for
example, is sufﬁcient for the protein's polymerisation into PHFs [4].
When exogenously supplied, this tau fragment can be internalised
by cells, engaging endogenous proteins to form toxic aggregates
which spread in prion-like cell-to-cell transmission [7,8,15,16].
High-yield expression of pure tau is critical for in vitro tauopathy
studies. However, the protein's expression and puriﬁcation are
complicated by its high aggregation and truncation tendencies, and
time-consuming and expensive methodologies [17]. Here, we
sought to identify parameters that would ensure optimalunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Primers used in site-directed mutagenesis of the wild type K18 construct to create
the FTPD-17 pathogenic mutations N279K and V337M. Mutated codons are
underlined.
Primer Sequence (50 to 30)
N279K_Forward GCAGATAATTAAAAAGAAGCTGGATCTT
N279K_Reverse ACCTTCCCGCCTCCCGGC
V337M_Forward AGGTGGCCAGATGGAAGTAAAATC
V337M_Reverse CCTGGTTTATGATGGATGTTG
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The following expression conditions were investigated: the choice
of E. coli host strain, induction temperature, duration of induction,
and the presence of glucose in the culture medium. Subsequently,
the newly established conditions were utilised for the large-scale
protein expression and puriﬁcation. The puriﬁed proteins were
characterised through circular dichroism analysis of secondary
structures and the assembly of Alzheimer-like PHFs.
2. Materials and methods
2.1. Cloning of K18 into pProEx plasmid
A pProEx-HTa-Myc-K18 plasmid was constructed for the re-
combinant expression of K18 tau and two FTPD-17 variants. In each
case, the K18 sequence was preceded by the Tobacco Etch Virus
(TEV) protease-recognition sequence ENLYFQG fused at the N-ter-
minus to a poly-histidine tag and a c-Myc tag (Fig. 1). This
arrangement enabled large-scale protein puriﬁcation using IMAC
and subsequent TEV protease cleavage.
The coding sequence of K18 was generated by polymerase chain
reaction using pCMV-FLAG-tau as template (a gift from Dr. Calum
Sutherland, University of Dundee, UK) and cloned between the EheI
and EcoRI sites of the pProEx-HTa plasmid (Invitrogen) containing
ampicillin-resistance and lacI-encoding genes (Fig. 1). Expression
was controlled by a trc promoter, and initiated with the addition of
isopropyl b-D-1 thiogalactopyranoside (IPTG). Plasmid sequences
were conﬁrmed by DNA sequencing (GATC Biotech AG, Konstanz,
Germany).
2.2. Site-directed mutagenesis (SDM)
The Q5® SDM kit (New England Biolabs) was utilised to create
the N279K and V337M pathogenic mutations in the K18 wild type
(WT) tau, according to manufacturer's instructions, using primers
listed in Table 1 (designed using the NEBaseChanger™ programme
http://nebasechanger.neb.com, version 1.2.3). Plasmids were
transformed into competent NEB-5a E. coli cells (a DH5a derivative)Fig. 1. The wild type K18 expression plasmid used in this study. (A) A schematic
representation of the pProEx-HTa plasmid into which the K18 tau construct was
cloned. The EheI and EcoRI restriction sites between which K18 was cloned are shown,
as well as the genes encoding the LacI repressor (lacI), ampicillin resistance (AmpR),
and origins of replication (f1Ori and pBR322 Ori). (B) Essential elements of the pProEx-
HTa-Myc-K18 plasmid are indicated. These include a trc promoter, a poly-histidine tag,
a TEV cleavage site and a c-Myc tag followed by K18.and grown overnight in Luria-Bertani (LB) broth containing 100 mg/
ml ampicillin in a shaking incubator with agitation (180 rpm) at
37 C. Plasmid DNA was isolated using the QIAprep Spin Miniprep
kit (QIAGEN GmbH, Hilden, Germany) according to manufacturer's
instructions. The presence of the mutations was conﬁrmed by DNA
sequencing as described above, using the primers listed in Table 2,
following which plasmid DNA was transformed into BL21(DE3)
*pRosetta cells.
2.3. Transformation of competent cells
Five nanograms of plasmid DNA was added to 50 ml competent
BL21(DE3)*pRosetta cells and incubated on ice for 30 min. Cells
were heat-shocked at 42 C for 30 s, followed by 2 min incubation
on ice. 950 ml LB broth was added and the mixture incubated at
37 C for 1 h. 40 ml of the mixture was plated on LB agar supple-
mented with ampicillin (100 mg/ml) and chloramphenicol (35 mg/
ml) and incubated overnight at 37 C.
2.4. Expression of the K18 tau constructs
Single colonies were inoculated into 10 ml selective LB broth
and grown overnight at 37 C. The following morning, 1 ml of the
overnight culture was inoculated into 50 ml selective LB broth and
grown at 37 C with 180 rpm agitation. Cultures were grown until
reaching OD600 ¼ 0.6e0.7, induced with 0.5 mM IPTG and grown
for a further 3 h. 1.5 ml aliquots were centrifuged at ~11,000g for
1 min, the pellet resuspended in 100 ml phosphate buffered saline
(PBS) and sonicated for 5 s at 10% power and re-centrifuged at
~11,000g for 5 min. All sonication was done in a Bandelin Sono-
puls 2070 sonicator. The soluble (supernatant) fraction was pipet-
ted into an Eppendorf tube for gel electrophoresis. The pellet was
resuspended in 500 ml PBS, sonicated (10% power, 5 s) and centri-
fuged (~11,000g for 5 min). The resultant pellet was resuspended
in 150 ml PBS, producing the insoluble fraction. Tau expression in
the soluble and insoluble fractions was analysed by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blotting (WB) as described below.
2.5. SDS-PAGE and WB
Protein samples were separated on standard 15% Tris-glycine
SDS-PAGE gels with (reducing gels) or without (non-reducing
gels) b-mercaptoethanol and 5 min heating at 95 C. Samples were
analysed against a protein ladder (P7712 or P7712S from New En-
gland BioLabs, size range ¼ 11e245 kDa) for 35 min at 200 V in a
Biorad Mini-PROTEAN Tetra system (BioRad Laboratories,Table 2
DNA sequencing primers.
Primer Sequence (50 to 30)
Sequencing primer 1 ACAGACCATGTCGTACTACC
Sequencing primer 2 AGGCGGCAGTGTGCAAATAG
T.K. Karikari et al. / Protein Expression and Puriﬁcation 130 (2017) 44e5446California, USA) and stained with Instant Blue (Coomassie-based
stain from Expedeon, Cambridge, UK) for 1 h at room temperature
(RT) with no washing steps required and imaged using a SynGene
G-Box imaging system. To identify tau-positive bands, WB was
performed prior to antibody detection as described below.
Gels were transferred overnight at 4 C or 2 h at RT onto
Amersham Hybond electrochemiluminescence nitrocellulose
membrane (GE Healthcare, Buckinghamshire, UK) and blocked for
15 min prior to 2 h incubation with primary antibody (1:5000
dilution, polyclonal rabbit anti-human tau A0024, Dako, Ely, UK).
Unbound antibody was removed by 5  5 min washes with 10%
TBS-Tween in distilled water before 2 h incubation at RT with
secondary antibody (goat anti-rabbit IgG 31460, Thermo Scientiﬁc,
UK, 1:5000 dilution) and the membrane washed as previously. For
WB to conﬁrm cleavage of the histidine tag, an anti-His antibody
(27-4710-01 from GE Healthcare, 1:2500 dilution) and rabbit anti-
mouse IgG (31450 from Thermoﬁsher, 1:5000 dilution) were used
as the primary and secondary antibodies respectively. Antibody
detection was performed using the Amersham electro-
chemiluminescence detection reagents according to the manufac-
turer's instruction and bands visualised by exposure to X-ray ﬁlm
(Fuji Medical X-ray Film Super RX) and developed in an AGFA Curix
60 processor (Agfa Healthcare, Greenville, SC, USA). Densitometry
analysis of protein bands was performed using ImageJ [18], and
differences compared using the Mann-Whitney test in Prism 6
(GraphPad Inc., CA, USA) at 5% signiﬁcance level.2.6. Large-scale expression of tau constructs
Large cultures were produced by inoculating 500ml selective LB
broth with 10 ml overnight cultures using the expression param-
eters described above. Cultures were subsequently centrifuged at
4 C for 10 min at 9800g. The resulting pellet was resuspended in
50mMNa2PO4 pH 7.5 and frozen until use. Prior to puriﬁcation, the
lysate was boiled at 70 C for 10 min to thaw, and protease inhibitor
cocktail (Roche Diagnostics, 1 tablet/~50 ml lysate), DNAse I and
5ml of 1 BugBuster® protein extraction reagent (Merck Millipore)
added. The mixture was left to stand at RT for 1 h, sonicated at 70%
power for 1min and centrifuged at 4 C for 30min at 48,000g. The
supernatant containing the soluble fraction (crude extract) was
decanted, ﬁltered through a 0.2 mm ﬁlter and puriﬁed as below.2.7. Protein puriﬁcation by immobilised metal afﬁnity
chromatography (IMAC)
A Ni-NTA column was used. Chelating sepharose resin (GE
Healthcare, UK) was charged with 10 mM NiCl2/CH3COONa pH 4.0
and equilibrated with buffer A (50 mM Na2PO4 pH 7.0, 500 mM
NaCl, 10 mM imidazole) before addition of the crude extract. The
columnwas re-washed with buffer A, followed by buffer B (50 mM
Na2PO4 pH 7.0, 500 mM NaCl, 25 mM imidazole) and the protein
eluted with buffer C (50 mMNa2PO4 pH 7.0, 500 mMNaCl, 500 mM
imidazole) followed by overnight dialysis in the presence of 25 mg/
ml TEV protease, against dialysis buffer (50 mM Tris HCl pH 7.5,
100 mM NaCl) to cleave the polyhistidine-TEV tag. The dialysed tau
was re-puriﬁed to isolate the TEV protease-cleaved tau. Brieﬂy, the
column was equilibrated with buffer A, the cleaved protein
collected as the ﬂow through upon elution and ultra-ﬁltered using
Vivaspin 20 (5 kDa cut off) where necessary. At each step of the
puriﬁcation process, aliquots were taken for SDS-PAGE and WB
analysis. Protein concentration and purity were estimated using the
Bicinchoninic acid assay (G-Biosciences, Missouri, USA) and SDS-
PAGE respectively.2.8. Preparation of Alzheimer-like PHF
A method adapted from Barghorn et al. (2005) [13] was used.
Brieﬂy, 200 ml reaction mixtures containing 12 mM tau, 10 mM
Na2PO4 pH 7.4, 50 mM ammonium acetate, 1 mM DTT and 6 mM
heparin (MW 6000) were prepared and incubated at 37 C for ~ 7
days to promote ﬁlament formation.
2.9. Circular dichroism (CD) spectroscopy
Following dialysis of the puriﬁed tau protein in Thermo Scien-
tiﬁc™ Slide-A-Lyzer™MINI Dialysis Device (10K MWCO) in excess
of 10 mM Na2PO4 pH 7.4 buffer as per the manufacturer's in-
structions, 10 mM samples were diluted in the same buffer and CD
spectra collected using a Jasco J-815 CD spectropolarimeter in a
1 mm path length cell. The response time was 1 s with a data pitch
of 0.1 nm and the scan speed was 100 nm/min. 32 spectra accu-
mulations were obtained for each sample at wavelengths ranging
from 190 nm to 280 nm and averaged. The high tension voltagewas
550 V throughout.
PHF samples were centrifuged at 100,000g for 1 h at 4 C,
supernatant removed and the pellet resuspended in 200 ml of
10 mM Na2PO4 pH 7.4. CD analysis on PHF samples was conducted
as described above. Secondary structure elements were estimated
using the DichroWeb Contin-LL (Provencher and Glockner method)
reference dataset 4 [19e21].
2.10. Transmission electron microscopy (TEM)
300-mesh Formvar carbon-coated copper grids (Agar scientiﬁc,
UK) were glow-discharged and 5 ml of 1:2 dilutions of ﬁlament
preparations pipetted onto the grid and allowed to bind for 1 min,
excess sample removed and 5 ml uranyl acetate added for 1 min and
excess removed. The grids were imaged using a JEOL-2100F
transmission electron microscope.
3. Results
3.1. Preparation of tau pathogenic mutants
The K18WT construct was used as a platform for the creation of
tau constructs carrying the N279K and V337M FTPD-17 mutations.
Bothmutations were single point: N279K¼ AAT (Asn)/ AAA (Lys)
and V337M ¼ GTG (Val)/ ATG (Met), and were conﬁrmed by DNA
sequencing and subsequent multiple sequence alignments to the
original K18 WT construct (Supplementary Fig. 1).
3.2. Comparison of tau expression in two different E. coli strains
Tau expression in two E. coli strains e BL21(DE3)*pRosetta and
NEB-5a e was compared (Fig. 2). The intention was to compare
expression in the former strain which is adapted for the expression
of eukaryotic proteins, with the latter strain lacking this property.
After IPTG induction, expressed tau proteins were positively iden-
tiﬁed with the anti-tau antibody used (Fig. 2A). SDS-resistant K18
WT monomers and dimers were approximately 22 kDa and 44 kDa
in size respectively, with shorter fragments most likely indicating
truncation products. The resistance of tau to denaturation by SDS
has been previously reported [22,23]. Note that the presence of the
c-Myc, poly-histidine and TEV tags, and the anomalous SDS-
binding property of tau inﬂuenced the observed size of puriﬁed
tau. Higher amounts of soluble monomeric tau were recorded in
the BL21(DE3)*pRosetta strain compared to NEB-5a, although this
difference was not signiﬁcant (two-tailed Mann Whitney test,
p ¼ 0.6; Fig. 2B). While comparable levels of monomeric tau were
Fig. 2. Representative Western blot analysis of K18 tau expression in the NEB-5a and BL21(DE3)*pRosetta E coli strains. (A) Dimerisation and truncation of expressed tau
protein were noticeable in both strains. (B) Densitometry analysis showing that soluble monomeric tau levels in the BL21(DE3)*pRosetta strain and NEB-5a were not signiﬁcantly
different (two-tailed Mann Whitney test, p ¼ 0.6). Data shown as mean ± standard deviation of three independent experiments. (C) Evaluation of K18 WT and K18 V337M
expression in the BL21(DE3)*pRosetta strain. Comparable levels of tau expression, aggregation and truncation were observed in the soluble and pellet portions of both constructs,
suggesting that the presence of the pathogenic mutation did not have detrimental effects on tau protein expression. S, soluble fraction; P, pellet (insoluble) fraction; IPTG, isopropyl
b-D-1 thiogalactopyranoside.
Fig. 3. Representative Western blot analysis showing the inﬂuence of induction
temperature on expression levels of K18 WT tau. Cultures of tau-encoding BL21(DE3)
*pRosetta cells were grown at 37 C until reaching OD600 ¼ 0.6. After IPTG induction,
the cultures were immediately split into three aliquots and grown at 25 C, 30 C or
37 C for 3 h. The yield of soluble monomeric K18 WT was highest in cultures grown at
37 C following induction, although aggregation and truncation also appeared fav-
oured at this temperature.
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BL21(DE3)*pRosetta (41.1 ± 18.8 and 42.4 ± 19.1 respectively),
expression in NEB-5a resulted in higher levels of monomeric tau in
the insoluble fraction compared to the soluble fraction (42.9 ± 22.1
and 31.9 ± 4.36 respectively; Fig. 2A and B), suggesting a higher
proportion of inclusion body formation in this host. For this reason,
all subsequent experiments were conducted using tau transformed
into BL21(DE3)*pRosetta. Note that the densitometry analysis was
focused on monomers as the most abundant and primary tau
protein species but due to the high tendency of the protein to form
aggregation and truncation products, this may not represent overall
tau production in some cases.
The effect of the V337M disease mutation on protein expression
was also measured, since this point mutation is sufﬁcient to reduce
the MT-binding ability of tau in vitro [9]. In this experiment, similar
levels of monomeric tau expressionwere observed for both K18WT
and the V337M variant, suggesting that the pathogenic mutation
did not affect expression levels (Fig. 2C). Furthermore, both pro-
teins shared tendencies to form aggregates and truncation prod-
ucts, indicating that the spontaneous aggregation and truncation
properties of tau were independent of this mutation (Fig. 2C).
3.3. Temperature optimisation for tau expression
Subsequently, conditions for protein expression in the
BL21(DE3)*pRosetta strain were investigated. The following pa-
rameters were studied: post-induction expression temperature,
length of induction, and media supplementation with glucose.
To identify an ideal expression temperature for K18 production,
an initial culture of K18 WT-expressing cells was divided into three
equal aliquots immediately after induction and grown for a further
3 h at 25 C, 30 C and 37 C. WB analysis showed that all three
temperatures were suitable for tau expression. 37 C was found to
be the best for soluble tau production, as the expression of full-
length monomeric K18 WT was highest at this temperature(Fig. 3). However, increasing temperature appeared to favour pro-
tein aggregation and truncation.
3.4. Induction length for optimum tau expression
Optimal incubation time can vary depending on the target
protein and the choice of expression system. To establish an opti-
mum induction length for K18 WT expression, aliquots of induced
cultures were taken at regular intervals post-induction and ana-
lysed by WB. Although no marked difference in monomeric tau
levels was recorded at the different timepoints, truncation products
and aggregates were least evident at 1 h (Fig. 4A).
Next, the growth curves of uninduced and induced cultures
were monitored to ascertain whether prolonged expression
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grew at a slightly faster rate post-induction, this difference
appeared minimal, suggesting that tau expression did not pose
signiﬁcant cellular toxicity to the bacterial system (Fig. 4B).3.5. Media supplementation with 0.2%w/v glucose
Glucose regulates the lac operon and may reduce promoter
“leakiness” (detectable expressionwithout induction) [24]. Glucose
may therefore be provided as an extra carbon source to enhance
growth of E. coli expressing a gene of interest. Addition of up to 1.0%
glucose has been shown to enhance protein yield [25]. For this
reason, the effect of media supplementationwith 0.2% glucose prior
to IPTG induction of tau expression was investigated. The level of
monomeric K18 WT was not signiﬁcantly enhanced by glucose
supplementation (p ¼ 0.6667; Fig. 5A and C). Similar ﬁndings were
also recorded for K18 with the two FTPD-17 variants (Fig. 5B).3.6. Puriﬁcation of tau constructs
After identifying optimum conditions for expressing K18, these
conditions were employed in growing larger cultures of tau that
were subsequently puriﬁed using IMAC. All three protein con-
structs (K18 WT, K18 V337M and K18 N279K) were successfully
puriﬁed using this system, followed by overnight dialysis and TEV
site cleavage. Tau expression and puriﬁcation were conﬁrmed by
SDS-PAGE and WB (Fig. 6). As expected, the crude extracts con-
tained tau in addition to contaminating cellular proteins (lanes
labelled CE in Fig. 6). After initial separation of the crude extracts,
the tau component was bound to the Ni2þ resin, leaving unbound
proteins to ﬁlter through (UPFT lanes in Fig. 6).Washing the column
with buffer B removed residual contaminants and loosely-bound
protein (lanes B1-B3 in Fig. 6). Proteins were eluted with buffer C
containing 500 mM imidazole (C1-C3 lanes in Fig. 6). and subse-
quently dialysed overnight with TEV protease and the puriﬁcationFig. 4. Time-course evaluation of K18WT expression in E. coli using optical density meas
37 C until reaching OD600 ¼ 0.6. The cultures were divided into two halves, and one portio
OD600 readings and aliquots for Western blotting taken periodically. (A) Soluble cell fractions
1 h post-induction but increased after this time point. (B) Growth curves of IPTG-induced
Arrow indicates point of induction.process repeated to isolate tau proteins with the TEV site cleaved.
Complete cleavage of the His tag was conﬁrmed in WB using an
anti-His antibody (Fig. 7). While the total tau antibody recognised
K18 WT with or without the His tag (Fig. 7A, lanes 2 and 1
respectively), the anti-His antibody had no recognition for K18 WT
and K18 N279K with the His tags cleaved (Fig. 7B, lanes 3 and 4
respectively) but for K18 WT with the His tag intact (Fig. 7B, lanes
5). Protein yield was up to ~5.5 mg/ml per 500 ml culture (Table 3).
WB showed that the tau constructs were puriﬁed both in the
monomeric and dimeric forms (and sometimes in higher oligo-
meric forms; Fig. 6), emphasising the characteristic tendency of the
protein to readily form aggregates. Contrary to the expression ex-
periments, truncation products were rarely observed in puriﬁed
proteins.3.7. CD assessment of secondary structure properties of the puriﬁed
tau
Following successful puriﬁcation of the tau proteins, K18 WT
and K18 V337M were characterised to compare their biochemical
properties to those previously reported [10,26]. Firstly, CD spec-
troscopy was used to investigate secondary structure conformation
of the puriﬁed tau. To assess the secondary structures of the tau
proteins in solution, their CD spectra were measured in the far-
ultraviolet spectral region (wavelength 190e280 nm) using pro-
teins dissolved in 10 mM phosphate buffer (pH 7.4) at RT. Previous
studies have reported that tau, in the mostly-monomeric state, is
inherently unfolded, with predominantly random-coil conforma-
tion [4,5,10,26,27]. Our analysis conﬁrmed this observation for the
puriﬁed proteins; CD spectra for both K18 WT and K18 V337M
showed minimum peaks around 200 nm (Fig. 8A and B), charac-
teristic of predominantly random coil structures [10,26]. Moreover,
the depth of the negative peaks were similar for both the WT and
mutant constructs, suggesting that the disease-associatedmutation
did not cause obvious changes in secondary structure of tau asurement andWestern blotting. Cultures of tau K18WT-expressing cells were grown at
n induced with 0.5 mM IPTG. Both cultures were subsequently incubated at 37 C, and
showing the expression of K18WT over time. Truncation products were least evident at
and uninduced cultures of tau, showing the same pattern of growth for both cultures.
Fig. 5. Media supplementation with 0.2% glucose did not signiﬁcantly enhance tau expression. BL21(DE3)*pRosetta cells expressing tau were grown in selective LB media in the
presence or absence of glucose. (A) Representative Western blot analysis of soluble cell fractions showing the expression of K18 WT in the absence and presence of 0.2% glucose. (B)
Western blot analysis of induced protein expression in K18 WT and its FTPD-17 variants (V337M and N279K). (C) Densitometry analysis of monomeric K18 WT expression in LB
media with or without glucose showed that there was no signiﬁcant difference in protein expression (two-tailed Mann Whitney test, p ¼ 0.6667, n ¼ 3).
Fig. 6. Analysis of IMAC-based tau puriﬁcation using SDS-PAGE followed by Western blotting. Cultures were grown until reaching OD600 ¼ 0.6, IPTG-induced and grown for a
further 1 h after which the expressed tau protein was recovered and puriﬁed. Aliquots taken at each step of the puriﬁcation process were analysed on 15% Tris-glycine SDS-PAGE
gels. (A), (D) and (F) show SDS-PAGE analysis of the puriﬁcation of K18WT, K18 V337M and K18 N279K respectively. (B) and (C) areWestern blots of K18WT puriﬁcation. (E) and (G)
Western blot analysis of the puriﬁcation of K18 V337M and K18 N279K respectively. Arrows indicate monomeric tau; black arrows point to uncleaved His-tagged tau while open
arrows refer to tag-free tau. M ¼ marker protein; CE ¼ crude extract; UPFT ¼ unbound protein ﬂow-through; B1, B2 and B3 ¼ wash fractions; C1, C2 and C3 ¼ eluted fractions;
DOT ¼ pooled eluted fractions dialysed overnight in the presence of TEV protease, against dialysis buffer; TR ¼ tau recovered from the second puriﬁcation process after TEV
cleavage. C ¼ K18 WT control protein from a previous preparation after the removal of breakdown products and aggregates, leaving homogenous monomeric tau.
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Fig. 7. Conﬁrmation of cleavage of the polyhistidine tag. (A) Western blotting using
the total tau antibody (A0024 from Dako) conﬁrmed the presence of tau in puriﬁed
K18 WT with and without the His tag cleaved (lanes 1 and 2 respectively). (B)Western
blotting using the anti-His antibody however recognised the His tagged K18 WT (lane
5) but not equal concentrations of K18 WT and K18 N279K with the His tags cleaved
(lanes 3 and 4 respectively).
T.K. Karikari et al. / Protein Expression and Puriﬁcation 130 (2017) 44e5450previously reported [4]. To estimate the relative contribution of
different secondary structure elements, the CD spectra were ana-
lysedwith the CONTIN algorithm in DichroWeb, which showed that
the secondary structures were dominated by random coils, with
traces of a-helices and b-sheets (Fig. 8C and D).3.8. Preparation of Alzheimer-like PHF and subsequent imaging
using negative-stain TEM
In order to validate their authenticity, Alzheimer-like ﬁlaments
were prepared from the recombinant proteins and visualised by
TEM. PHFs were prepared in the presence of the reducing agent DTT
and the polyanion inducer heparin. The reaction was carried out in
10 mM Na2PO4 pH 7.4 buffer. The use of a non-chlorine-containing
buffer enabled subsequent CD investigations on the prepared PHF
without having to change buffers as was previously done [10]. TEM-
based structural examination suggested that the ﬁlaments con-
sisted of distinct features including two strands wound round each
other, with crossover points every few nanometers (Fig. 9) in line
with previous observations [5,28].
Subsequently, the ﬁlamented tau samples were analysed by CD
to assess whether PHF assembly induced a shift in secondary
structure composition as suggested [26]. The CD spectra forTable 3
Summary of studies on expression and puriﬁcation of recombinant tau.
Study Tau isoform or construct
studied
Puriﬁcation method used Y
This work Wild type K18 and its N279K
and V337M frontotemporal
dementia variants
Ni2þ afﬁnity chromatography U
p
N
Tepper et al.
(2014)
[39]
2N4R (longest tau isoform in
the adult human brain)
Tau expressed in Sf9 cells was puriﬁed
by size exclusion and anion exchange
chromatography
5
Geodert and
Jakes
(1990)
[23]
The six human tau isoforms Ammonium sulphate precipitation and
ion exchange chromatography
3
Barghorn
et al.
(2005)
[13]
Tau isoforms and constructs
including K18
Gel permeation and cation exchange
chromatography
1
c
i
Csokova
et al.
(2004)
[17]
221-441 fragment of tau Cation exchange, anion exchange and
size exclusion chromatography
4ﬁlamented tau showed a shift in peak to approximately 220 nm,
which is indicative of b-sheet formation (Fig. 8). While the soluble
fractions in the PHF preparation samples consisted of monomers
and low molecular weight oligomers, the insoluble PHF was pre-
dominantly made up of higher molecular weight species that were
not noticeable by WB (Fig. 9F), consistent with previous observa-
tions [29].4. Discussion
Tau protein has been the subject of intensive research because of
its physiological importance in stabilising MTs, supporting axonal
transport, neurite outgrowth and other processes involved in
neuronal cell biology [2,30,31]. In addition, toxic aggregation of WT
tau and its FTPD-17 variants is the primary hallmark of Alzheimer's
disease and other tauopathies [2]. Efﬁcient production of recom-
binant tau is a pre-requisite for the in vitro and some in vivo
modelling of these diseases. Insufﬁcient yield of this target protein
can result in several experimental pitfalls. In this study, we inves-
tigated parameters that can affect the expression and puriﬁcation
of WT and FTPD-17 pathogenic tau, in an attempt to identify ways
to increase the yield of pure tau for downstream applications. It was
shown that the presence of the V337M and N279K pathogenic
mutations appeared not to affect monomeric tau expression, which
was greatest at 37 C induction temperature compared to 25 C and
30 C. Build-up of truncation products and aggregates was least
evident at 1 h post-induction, compared to up to 13 h post-
induction. Supplementing the growth medium with 0.2% glucose
did not signiﬁcantly affect the percentage of monomeric tau pre-
sent. The expressed protein was puriﬁed using IMAC and charac-
terised by CD and PHF analysis. Our ﬁndings show that the
described method led to the production of authentic tau proteins,
which followed the known biochemical and biophysical properties.
This report provides a reliable method for efﬁcient expression and
puriﬁcation of tau that would be useful for further studies.
The BL21(DE3)* pRosetta strain used in this study was deﬁcient
in RNAseE, and genetically modiﬁed to be Lon and OmpT protease-
deﬁcient, making it suitable for high-yield expression of foreign
genes in bacteria. WB showed that using this strain did not
signiﬁcantly enhance the amount of monomeric tau compared to
NEB-5a (Fig. 2). This was possibly due to the high propensity of tau
to aggregate and form truncated peptides, thus preventing efﬁcient
evaluation of monomeric tau yield. Whilst 37 C appeared optimalield Purity
p to ~5.5 mg/ml, 4.0 mg/ml and 3.5 mg/ml protein
er 500 ml culture for K18 WT, K18 V337M and K18
279K respectively
Up to 99% purity for
monomer only and 95% for
monomer-oligomer mix
e10 mM (subsequently concentrated to ~50 mM) Not indicated
0e60 mg/ml culture Up to 95% purity
0e100 mg protein/10 L
ulture (speciﬁc concentration for K18 not
ndicated)
95% for monomer-oligomer
mixtures and 99% for
monomer only
e8 mg protein/500 ml culture Up to 98% purity
Fig. 8. Characterisation of the puriﬁed tau proteins using circular dichroism spectroscopy and the preparation of Alzheimer-like paired helical ﬁlaments. (A) and (B) Circular
dichroism spectra within the far-UV region were obtained from K18 WT and K18 V337M monomers (blue curves) and insoluble ﬁlaments (red curves). The spectra for monomers
showed negative peaks at about 200 nm. Filament formation induced a positional shift in the peak towards 220 nm. (C) and (D) The circular dichroism data gathered were subjected
to computational analysis to estimate secondary structure content. The CONTIN algorithm in the DichroWeb database predicted that the monomeric tau were predominantly
random-coiled (turns and unordered). The preparation of paired helical ﬁlaments induced secondary structure re-organisation towards b-sheets. (For interpretation of the ref-
erences to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 9. Representative electron micrographs showing negative-stained Alzheimer-like ﬁlaments of distinct morphologies prepared from the puriﬁed tau proteins. Panels
(A), (B) and (C) are from K18 WT while (D) and (E) are from K18 V337M. Panel A shows paired helical ﬁlaments of varying width. Panels B and D contain straight ﬁlaments with no
obvious periodicity. Panels C and E display spiral-like paired helical ﬁlaments. Arrowheads indicate possible peak-to-peak crossover points. (F) Following heparin-induced tau
aggregation, ﬁlament samples were ultracentrifuged to isolate soluble species from insoluble aggregates (paired helical ﬁlaments; PHF). Western blot analysis suggested that the
soluble fraction consisted of a heterogeneous mix of monomers and oligomers while the insoluble aggregates consisted mostly of higher molecular weight ﬁlaments that were not
detectable by Western blotting.
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with temperature (Fig. 3). This corroborates previous reports that
tau polymerisation is most efﬁcient at high temperatures [14]. A
relatively short induction time of 1 h was optimal for the amount of
monomeric protein yields achieved and a concentration of 0.1 mM
e 1 mM IPTG was sufﬁcient to induce expression (data not shown).
Media supplementation with glucose did not signiﬁcantly enhance
expression yield, suggesting that the strain can be used for tau
production without glucose (Fig. 5). A common observation
throughout the expression-optimisation experiments was the high
tendency of the tau constructs to form truncation products, in bothstrains studied (Figs. 2e5). This possibly could have been reduced
by the addition of protease inhibitors to the growthmedium or lysis
buffer, notwithstanding the reported protease resistance of the tau
repeat domain [32]. However, this step was omitted to allow the
proteins to be observed in a native-like state. It was also observed
that a considerable portion of the protein existed in the pellet
fraction, which could not be recovered by additional sonication
(Fig. 2). This was likely as a result of the formation of inclusion
bodies or insoluble aggregates and not due to insufﬁcient cell lysis,
as reported for another protein [33].
The puriﬁed tau proteins were characterised using CD
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(Fig. 7). The CD data revealed that the puriﬁed tau proteins were
inherently unfolded, showing negative peaks at approximately
200 nm. For direct evidence of ﬁlament formation, samples were
negative-stained and imaged by TEM, which indicated that the
puriﬁed tau proteins were capable of forming ﬁlaments. Filament
formation was induced with the addition of heparin; the role of
heparin as an inducer of PHF formation has been characterised [34].
Filament formation is promoted by hexapeptide motifs at the
beginning of the second and third tau repeats [35], both of which
were intact in the 4R tau constructs used [27]. Figs. 8 and 9 indicate
that the tau proteins produced were able to form ﬁlaments as ex-
pected, and that the ﬁlaments consisted of high molecular weight
oligomers compared to pre-ﬁlament species. The observed struc-
tural shift in CD spectra following tau aggregation can also be
achieved by incubating tau at physiological temperatures with or
without heparin, although incubation times are lengthened in the
absence of heparin [27,36].
An advantage of the method reported here is that it enables the
production of tau oligomers and monomers (the toxicity of both of
which is currently under intense investigation) through one- or
two-step puriﬁcation protocols. The ﬁrst puriﬁcation step produces
polyhistidine-tagged tau; the tag can be removed following TEV
protease treatment during dialysis. We have conﬁrmed that both
His-tagged and tag-free tau proteins prepared using the described
protocol are fully functional in terms of their aggregation tendency,
ability to form Alzheimer-like ﬁlaments, and secondary structure
features. These ﬁndings are in agreement with earlier studies that
reported the use of untagged and His-tagged tau for in vitro and cell
culture investigations [36e39], further conﬁrming the authenticity
of the proteins produced using our simpliﬁed protocol.
Whether or not the puriﬁed tau should undergo further pro-
cessing before utilisation for functional studies would depend on
the intended use. The preparation of monomer-oligomer mixtures,
described in this report, could be used for many studies. However, if
exclusively monomeric tau is required (as in Fig. 6C lane C), then it
is possible to remove truncation products and aggregates by size
exclusion chromatography. It is important to be certain about the
nature of puriﬁed tau being used for downstream applications
(whether consisting exclusively of monomers, oligomers or a
heterogenous mixture of the two) since seemingly conﬂicting re-
sults have been reported for the toxicity-seeding potential of
monomeric and oligomeric tau [7,8,40].
Historically, there has been a debate as to which tau protein
species is the most toxic to cells e whether monomers, oligomers,
PHF or NFT [41,42]. Recent attempts to address this question have
also sought to understand if tau toxicity and pathology spread in a
prion-like manner. In such studies, recombinant forms of the
various protein species are injected into the brains of living
experimental animals or extracellularly added to neuronal or
neuron-like cells, and their ability to be internalised, secreted and
co-aggregate with endogenous proteins monitored in real time
[43]. Converging evidence has mostly suggested that oligomeric tau
are the early-stage species required to initiate the trans-cellular
spread, toxicity and associated learning and memory impair-
ments [8,44,45], although others have reported that tau monomers
are the fundamental toxic species [7]. Although the transcellular
spread of tau pathology has become awell-known, experimentally-
conﬁrmed phenomenon, the mechanisms through which this
process occur have however remained elusive. It was recently re-
ported that the internalisation of tau K18 ﬁbrils occurs via binding
with heparan sulphate proteoglycans [46] whilst the extracellular
release of 4R0N tau occurs by exocytosis mediated by interaction
with the DnaJC/Hsc70 molecular chaperone complex [47]. It how-
ever remains unknown as to whether all tau isoforms andfragments and their frontotemporal dementia variants are intern-
alised and secreted through these same processes. As the scope of
research in this area grows, the importance of recombinant tau will
undoubtedly increase. Certainly, recombinant tau proteins of the
highest purity and yield will be essential to produce reliable and
reproducible data in future studies investigating the cellular
mechanisms involved in the spread of tau toxicity as well as the
in vitro structural, biochemical and biophysical aspects of the pro-
tein's ability to cause disease. The present study has demonstrated
a simple protocol for the preparation of tau K18 proteins for such
investigations. This is the ﬁrst report that focuses speciﬁcally on the
expression and puriﬁcation characteristics of K18 tau. Although
Barghorn et al. [13], earlier described a method that combines gel
permeation and size exclusion chromatography for the puriﬁcation
of tau isoforms and constructs, a general protein yield range was
provided (10e100 mg/10 L culture), with no speciﬁc value given for
K18 tau. Protein yields for the tau constructs and isoforms vary [13],
possibly due to the different structural and functional characteris-
tics exhibited by these proteins. For this reason, studies dedicated
to documenting expression and puriﬁcation approaches for each
tau protein is necessary to inform future research. Such reports are
available for the adult human brain tau isoforms and some trun-
cation constructs (Table 3), although the procedures described
mostly depend onmethodologies that are unavailable in many labs.
In contrast, the protocol described in the present study makes use
of a simple, inexpensive approach to purify both WT and mutant
K18 tau proteins in high yield, without compromising on the purity.
This protocol can be adapted for the preparation of the other tau
proteins. In fact, we have successfully used this protocol in our
laboratory to express and purify several other tau proteins,
including K18 and the full length isoform carrying FTPD-17 muta-
tions not described here, with similar protein quality and yield
(data not shown).
5. Conclusion
We have investigated speciﬁc parameters affecting the pro-
duction of the recombinant tau protein, reporting on conditions
that may ensure optimal expression. Using these parameters, the
tau MT repeat domain (K18) and two frontotemporal dementia
variants were expressed and puriﬁed, leading to pure proteins of
high concentrations. The puriﬁed proteins were natively unfolded
and followed the classical ﬁbrillisation pathway to form mature
PHFs. The formation of ﬁlaments initiated a shift in secondary
structure re-organisation from mostly random coils towards b-
sheet formation. As such, this report demonstrates efﬁcient
methods for the production of tau protein that can be used in
in vitro and in vivo studies.
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